MEDIGEN Business Summary

Medigen Biotechnology Corp (3176.TWO) operates as a diversified biopharmaceutical entity generating revenue through technology licensing, contract technical services, and the commercial sale of molecular diagnostic reagents and generic medicines. The company’s operations are structured into four primary segments: the Nucleic Acid Department, which provides HLA typing reagents and automated testing platforms; the New Drug and Vaccine R&D unit, focused on oncology pipelines such as Mupafostat (Phase III for liver cancer) and OBP-301 (Telomelysin); the Cytotherapy Department, specializing in natural killer (NK) and T-cell therapies; and a Generic Drug and Aesthetic Medicine division. Medigen maintains a mid-tier market position in Taiwan’s biotech sector, competing directly with Adimmune Corp (4142.TW), TaiMed Biologics (4147.TWO), OBI Pharma (4174.TWO), and Mycenax Biotech (4726.TWO) by leveraging a vertically integrated model that spans from early-stage discovery to clinical diagnostics. The company is led by Founder, Chairman, and President Dr. Stanley Chang (Shi-Chung Chang), a prominent figure in Taiwanese medicine who previously served as the Dean of the College of Medicine at Tzu Chi University and Director of Urological Surgery at Tzu Chi Hospital. Supporting the executive leadership is General Manager Alarng Chang and Assistant Vice President of Operations Arlene Chiang, who serves as the primary corporate spokesperson. The Board of Directors includes strategic industry figures such as Tse-Ling Chang, Chairman of Everspring Industry, and is backed by notable institutional investors including the Yuen Foong Yu (YFY) Group and Blackhawk Growth Corp. This leadership team combines deep clinical expertise from National Taiwan University Hospital with cross-sector experience in international business operations and biotechnology governance.